European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Companies

AbbVie

AbbVie Inc.

HQ
United States
Status
active
Listing
Listed · ABBV
Founded
2013
Current stage
commercial

sec.govregistryverified 2026-11-02

Notes on the record

Acquirer in D003-abbvie-gilgamesh-2025 and counterparty to the 2024 option in D004-abbvie-gilgamesh-option-2024. Added 2026-09-23 so Issue 15 can carry the ABBVIE tag: entity tags derive from this file and the build refuses a tag with no row, which is DATA LAYER rule 1 enforced at build time. Lead psychedelic asset is bretisilocin (GM-2505), renamed ABBV-2505 after the acquisition closed in October 2025. RE-VERIFIED 2026-11-02, no field changed: EDGAR CIK 1551152, Q3 8-K 0001551152-26-000033 (2026-10-30) EX-99.1 has 0 hits for bretisilocin and Gilgamesh; 8-Ks of 2026-10-05 (Items 2.02, 9.01) and 2026-10-15 (Item 5.02) not read; Q3 10-Q not filed as of 2026-11-02 15:51Z. Supersedes the row verified 2026-09-23 (kept), per DATA LAYER rule 4.

Assets

No asset in data/assets.csv names this company as owner.

Registered trials

No row in data/trials.csv resolves to this company's assets.

Deals

In the briefing

1 issue tagged ABBVIE.

Record history